Innovating epilepsy care
At Epiminder, we strive to transform epilepsy management through cutting-edge technology and patient-focused solutions.
Discover the journey of innovation at Epiminder since 2017
Epiminder was founded in 2017 by Professor Mark Cook as a research collaboration between the Bionics Institute, the University of Melbourne, St Vincent's Hospital Melbourne and Cochlear.
The partnership combined the technological expertise in epilepsy seizure monitoring of the three research institutions with Cochlear's proficiency in implant design, development and manufacturing.
Professor Mark Cook examining the Minder Implant device, the world's first FDA-authorised* implantable continuous EEG monitoring systemPicture: Aaron Francis, The Australian, May 7, 2021
Key milestones in our journey
Since our founding in 2017, Epiminder has been dedicated to revolutionising epilepsy care. Our innovative technology aims to empower patients and improve their quality of life.
2017
Epiminder founded by Bionics Institute, Cochlear, St Vincent's Hospital and Melbourne University.
2017
Epiminder founded by Bionics Institute, Cochlear, St Vincent's Hospital and Melbourne University.
2019
Epiminder develops prototype Minder implantable continuous EEG monitoring (iCEM) device, a multi-year duration ssEEG unit.
2019
Epiminder develops prototype Minder implantable continuous EEG monitoring (iCEM) device, a multi-year duration ssEEG unit.
2019
First of kind UMPIRE clinical study of Minder commences at leading tertiary research hospitals in Victoria, Queensland and New South Wales.
2019
First of kind UMPIRE clinical study of Minder commences at leading tertiary research hospitals in Victoria, Queensland and New South Wales.
2023
Minder receives FDA "Breakthrough" designation, for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Device Designation (BDD) program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review.
2023
Minder receives FDA "Breakthrough" designation, for medical devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The Breakthrough Device Designation (BDD) program is intended to help patients have more timely access to medical devices by expediting their development, assessment, and review.
2023
Professor Cook received the Order of Australia in recognition of his distinguished service to neurological medicine and research through contributions to the treatment of epilepsy.
2023
Professor Cook received the Order of Australia in recognition of his distinguished service to neurological medicine and research through contributions to the treatment of epilepsy.
2024
UMPIRE clinical study completes, with results demonstrating that Minder is both safe and has signal detection equivalent to a scalp EEG. Minder achieves a significant milestone, having recorded continuous EEG for five years in a study participant. To date, this is the longest continuous EEG recording ever captured.
2024
UMPIRE clinical study completes, with results demonstrating that Minder is both safe and has signal detection equivalent to a scalp EEG. Minder achieves a significant milestone, having recorded continuous EEG for five years in a study participant. To date, this is the longest continuous EEG recording ever captured.
2025
Epiminder received FDA marketing authorization via the De Novo pathway allowing its sale and marketing in the US.
2025
Epiminder received FDA marketing authorization via the De Novo pathway allowing its sale and marketing in the US.
Executive leadership
Our leadership team brings together expertise from neurology, biomedical engineering, and healthcare technology.
Rohan Hoare
Chief Executive Officer & Director
Prof Mark Cook, AO
Chief Medical Officer
Dr John Heasman
Chief Operating Officer
Toby McSweeney
Chief Technology Officer
Dr Tracy Cameron
VP, Clinical & Regulatory
Chip Moebus
VP, Market Access
Steven Ringo
VP, IT & Security
Board of Directors
Philip Binns (Chair)
President, Life Science and Applied Markets Group, Agilent Technologies
Robert Klupacs
Chief Executive Officer, Bionics Institute
Patricia O'Rourke
National CEO, Hospital Division, St Vincent's Health Australia
Catherine Picard
VP, Advanced Innovation & Strategic Investments, Cochlear
Mark Phelps
VP, Customer Software Development, Cochlear
Karen Campitelli (Company Secretary)
Chief Operating Officer, Bionics Institute
In proud partnership with
